What is an appropriate alternative to atenolol for treating systemic hemangioma in a child?

Alternative Beta-Blocker for Infantile Hemangioma When Atenolol is Not an Option

If atenolol cannot be used for treating infantile hemangioma in a child, propranolol is the definitive alternative and should be considered the first-line agent, as it is FDA-approved specifically for this indication and demonstrates superior efficacy with a 95% mean clearance rate. 1

Primary Recommendation: Propranolol

The 2019 American Academy of Pediatrics clinical practice guideline establishes oral propranolol as the treatment of choice for infantile hemangiomas requiring systemic therapy (Grade A, strong recommendation). 1 This represents the gold standard, not atenolol, making propranolol the appropriate choice when moving away from atenolol.

Dosing Protocol for Propranolol

• Target dose: 2-3 mg/kg/day divided into 2-3 daily doses 1
• Starting dose: 0.6 mg/kg twice daily, gradually increased over 2 weeks to maintenance dose of 1.7 mg/kg twice daily (3.4 mg/kg/day total) 1
• Treatment duration: Minimum 6 months, often continued until 12 months of age 1
• The 3 mg/kg/day regimen for 6 months showed superior outcomes with 60% complete/nearly complete resolution versus 4% with placebo 1

Efficacy Comparison

Network meta-analysis data clearly demonstrates propranolol's superiority 1:

• Propranolol: 95% clearance (95% CI: 88-99%)
• Atenolol: 56.5% excellent response in available data
• Topical timolol: 62% clearance
• Oral steroids: 43% clearance

Recent 2023 meta-analysis confirms propranolol achieves significantly higher complete response rates than atenolol (85.4% vs 73.3%, P = 0.0004), though this comes with increased adverse events. 2

Alternative Beta-Blocker: Nadolol

If propranolol is contraindicated or not tolerated, nadolol represents the next best alternative. 3, 4

Advantages of Nadolol

• Longer half-life allowing once or twice daily dosing, improving adherence
• Reduced CNS penetration compared to propranolol, potentially fewer neurocognitive side effects (less sleep disturbance, agitation)
• One small study showed greater efficacy than propranolol, though strength of evidence is low 1
• Comparable efficacy to propranolol in limited available data 5, 4

Limitations

• Not FDA-approved for infantile hemangioma
• Limited data on standardized dosing protocols
• Fewer long-term safety studies compared to propranolol

Critical Pre-Treatment Evaluation

Before initiating any beta-blocker, assess for contraindications 1:

Absolute contraindications requiring subspecialty clearance:

• Cardiogenic shock or heart failure
• Sinus bradycardia or heart block >first degree
• Known asthma/reactive airway disease
• Known hypersensitivity to the agent

Special populations requiring caution:

• Infants <5 weeks of age or postconceptional age <48 weeks
• Segmental facial hemangiomas (PHACE syndrome risk): Obtain brain MRI/MRA and echocardiography before full-dose therapy; start at 0.5 mg/kg/day until imaging complete 1, 6
• Large segmental hemangiomas >5 cm require MRI/MRA of head/neck and echocardiography 1

Topical Timolol for Select Cases

For small, thin, superficial hemangiomas, topical timolol 0.5% gel/solution applied twice daily offers a non-systemic alternative with 62% clearance rates. 1 This avoids systemic side effects entirely but is inappropriate for deep, large, or rapidly proliferating lesions.

Side Effect Profile Considerations

Propranolol has significantly more adverse events than atenolol (pooled odds ratio 2.70,95% CI 1.90-3.84), particularly 2:

• Agitation and sleep disturbances (P = 0.0245)
• Bronchial hyperreactivity (P < 0.0001)
• Hypoglycemia risk (monitor feeding, avoid fasting)
• Bradycardia and hypotension

However, these risks are acceptable given the superior efficacy and the potential for permanent disfigurement if hemangiomas are inadequately treated. The window for optimal treatment is narrow—most rapid growth occurs between 1-3 months of age, with growth completed by 5 months. 1

Common Pitfalls to Avoid

1. Delaying treatment: Refer by 1 month of age for high-risk hemangiomas (facial, periorbital, airway, ulcerated, or >5 cm segmental)
2. Inadequate dosing: Using <2 mg/kg/day propranolol reduces efficacy
3. Premature discontinuation: Treatment typically requires 6-12 months; stopping at first sign of improvement often leads to rebound growth
4. Missing PHACE syndrome: Always image large segmental facial/scalp hemangiomas before full-dose beta-blocker therapy
5. Ignoring cardiac contraindications: Obtain ECG and consider cardiology consultation if any cardiac history or examination concerns

Clinical Algorithm

1. First choice: Propranolol 2-3 mg/kg/day (FDA-approved, highest efficacy)
2. If propranolol contraindicated or intolerable side effects: Nadolol (longer half-life, less CNS penetration)
3. If only small/superficial lesions: Topical timolol (avoids systemic effects)
4. If all beta-blockers contraindicated: Systemic corticosteroids (historical standard, now second-line with 43% clearance) 1

The evidence unequivocally supports propranolol as the alternative to atenolol, not the reverse. Atenolol should only be considered when propranolol-specific contraindications exist (primarily CNS side effects or need for once-daily dosing to improve compliance).